Ozempic 2 mg Shows 6% Lower Cardiovascular Risk vs Mounjaro in Real-World Study
NVO is trading near its 52-week low of $35.12 (9.4% above the low).
Summary
Novo Nordisk presented real-world data showing Ozempic 2 mg reduced major adverse cardiovascular events by 6% compared to Lilly's Mounjaro in type 2 diabetes patients. The analysis covered over 630,000 adults from a U.S. claims database, with follow-up at 24 months. This is the first head-to-head cardiovascular outcomes comparison between the two GLP-1s, and it directly challenges Lilly's positioning of Mounjaro as superior. The result could influence prescribing patterns in the highly competitive diabetes market. The study was presented at the European Association for the Study of Diabetes annual meeting. Safety outcomes were not assessed in this analysis.
At the time of this announcement, NVO was trading at $38.43 on NYSE in the Life Sciences sector, with a market capitalization of approximately $169.6B. The 52-week trading range was $35.12 to $64.16. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Seeking Alpha.